China has included 17 cancer drugs on the medical insurance list, the country’s state medical insurance administration announced on Wednesday.

　　中国国家医疗保险总局周三宣布，中国已将17种抗癌药物列入医疗保险名单。

　　The price of the 17 drugs dropped 56.7 percent averagely compared to the average retail price. And, they have been priced lower than the market prices in the neighboring countries and regions, remarkably reducing the economic burden of people battling cancer in China.

　　与平均零售价相比，这17种药品的价格平均下跌了56.7%。而且，它们的价格已经低于在中国邻国地区的市场价格，这大大减轻了中国癌症患者的经济负担。

　　This June, China’s drug authority launched a new round of negotiations with pharmaceutical companies on the inclusion of cancer drugs for medical insurance.

　　今年6月，中国药监局启动了新一轮与制药公司的谈判，内容是将抗癌药物纳入医疗保险。

　　44 cancer drugs that were not covered in the list were reviewed during the negotiations, and 17 drugs were finally selected to be added on the list.

　　在谈判中再次审议了此前44种未列入清单的癌症药物，最后选定17种药物列入清单。

　　All of them are clinically necessary, effective, and urgently needed for cancer treatment.

　　它们都是临床上治疗癌症所必需的、有效的和迫切需要的药物。

　　The move also reflects the country’s support for medical innovation and stronger push for research and development. 10 of the 17 newly included drugs have been publicly available since last year.

　　此举也反映出中国对医疗创新的支持，以及对医疗研发的更大推动。自去年以来，新纳入的17种药物中有10种已经公开上市。